Covid-19 Vaccine: Second AstraZeneca Volunteer Reportedly Suffers Rare Neurological Condition
by Fabio Giuseppe Carlo Carisio
The devil makes the pots but not the lid. While the theory of the genetically modified organism built in the laboratory is becoming more and more concrete on the origin of the SARS-2 virus, here is the second hitch for one of the leading companies in the production of vaccines, the AstraZeneca of Anglo-Swedish ownership but actually controlled by the same American and Zionist shareholders of the Weapons Lobby (as demonstrated in previous investigations).
Big Pharma stumbles upon a second case of adverse reaction in a few days which, however, claims not to be related to the Covid-19 vaccine being tested. While a Hong Kong virologist confirms that this new Coronavirus strain was man-made, as part of those “dual-use” research for vaccine but also military bioweapon, as claimed by a Nobel Prize for Medicine, a former director of the British counter-intelligence MI6 and a NATO consultant bio-engineer, here is another incident for the multinational already known for cases of doping, suicide and other serious violations of drug laws.
The problem is looming huge for Europe which has already booked 400 million doses of the Oxford University vaccine, developed by the Jenner Institute, of which AstraZeneca acquired the distribution but then blocked clinical trials after a first very serious spinal cord infection (which could cause paralysis in the guinea pig. human) to which is added a second dramatic case…
from Russia Today
The company published details of the trials on Saturday, after facing criticism over the lack of transparency surrounding the testing of the much-anticipated vaccine against the virus, which has so far infected more than 30.8 million people and caused over 958,000 fatalities worldwide.
The first participant of the British trials – which are being conducted in conjunction with Oxford University – fell ill after receiving one dose of the experimental vaccine in July.
The female volunteer was later diagnosed with transverse myelitis, a rare inflammatory disease that affects the spinal cord, causing weakness, sensory alterations, and autonomic nervous-system dysfunction. The company’s spokeswoman later told the media the volunteer had undiagnosed multiple sclerosis, and the trials resumed.
The second female recipient of the vaccine suffered complications after the follow-up dose in September. AstraZeneca didn’t confirm her diagnosis, but a source told the New York Times it was also transverse myelitis.
On September 6, trials of the drug were paused again, after the second woman felt ill, but they resumed in Britain, Brazil, India, and South Africa less than a week later. The US hasn’t yet green-lighted the continuation of the test, however.
AstraZeneca, which has administered its vaccine to some 18,000 people worldwide, said in internal documents that the two cases of the illness were “unlikely to be associated with the vaccine, or there was insufficient evidence to say for certain that the illnesses were or were not related to the vaccine.”
Transverse myelitis is a serious and rare disease, and its repeated cases among the participants of the trials may well see AstraZeneca losing its vaccine bid all together.
AstraZeneca’s vaccine uses a monkey adenovirus that shares a gene with the Covid-19 coronavirus. It’s an untested method of vaccine development, according to Kirill Dmitriev, CEO of the Russian Direct Investment Fund that bankrolled the Russian vaccine development.
Unlike AstraZeneca’s jab, Russia’s Sputnik V, the world’s first registered vaccine, uses human adenoviruses as a vector – an extensively studied approach.
Earlier this month, respected British medical journal The Lancet published the Russian Ministry of Health’s Sputnik V study, showing the vaccine to be 100 percent effective, producing antibodies in all 76 participants of early-stage trials.